Europe Gas Exchange Pulmonary Function Testing Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Europe Gas Exchange Pulmonary Function Testing Market Size

• The Europe gas exchange pulmonary function testing market size was valued at USD 184.19 million in 2024 and is expected to reach USD 328.49 million by 2032, at a CAGR of 7.50% during the forecast period
• The market growth is largely fuelled by the growing adoption and technological progress within respiratory diagnostics and pulmonary monitoring technologies, leading to increased digitalization and precision in both hospital and clinical settings
• Furthermore, rising demand for early detection and monitoring of chronic respiratory conditions such as COPD, asthma, and interstitial lung diseases is establishing gas exchange pulmonary function testing (PFT) as a critical diagnostic tool across Europe. These converging factors are accelerating the uptake of gas exchange PFT systems, thereby significantly boosting the industry's growth

Europe Gas Exchange Pulmonary Function Testing Market Analysis

• Gas exchange pulmonary function testing systems, which assess gas diffusion and distribution in the lungs, are becoming essential diagnostic tools in modern respiratory care for both hospital and outpatient settings, owing to their ability to detect early signs of chronic pulmonary disorders, including COPD, interstitial lung disease, and pulmonary hypertension
• The rising demand for these systems is primarily driven by the increasing prevalence of respiratory diseases, growing elderly population, and technological advancements in pulmonary diagnostics, particularly in non-invasive, portable systems
• The U.K. dominated the Europe gas exchange pulmonary function testing Market with the largest revenue share of 26.8% in 2024, supported by a robust NHS infrastructure, strong public awareness programs, and widespread use of pulmonary function testing in routine respiratory assessments. National lung health initiatives and the integration of digital diagnostics into primary care further strengthen its leadership position
• Germany is expected to be the fastest-growing country in the Europe gas exchange pulmonary function testing market during the forecast period, driven by increased investment in healthcare digitization, rising clinical research on rare lung disorders, and high adoption of advanced diagnostic tools in tertiary care hospitals and specialty respiratory clinics
• The diffusion capacity test segment accounted for the highest market share of 64.3% in 2024, due to its essential role in diagnosing diseases such as pulmonary fibrosis and emphysema. Its non-invasive methodology and wide-ranging clinical applicability have solidified its dominance in pulmonary function testing

Report Scope and Europe Gas Exchange Pulmonary Function Testing Market Segmentation

Europe Gas Exchange Pulmonary Function Testing Market Trends

“Growing Demand for Integrated and Automated Diagnostic Systems”

• A significant and accelerating trend in the Europe gas exchange pulmonary function testing market is the integration of advanced technologies with pulmonary diagnostic systems, enabling more precise, efficient, and user-friendly testing workflows across hospitals and specialty clinics
  • For instance, several European healthcare providers are now adopting portable and stationary testing systems equipped with real-time data analysis features. These platforms not only streamline the testing process but also improve diagnostic accuracy for conditions like COPD, pulmonary hypertension, and interstitial lung diseases
• Many devices now incorporate intelligent algorithms that assist clinicians in interpreting diffusion capacity and gas distribution test results. These smart systems can flag anomalies and suggest next steps, ultimately enhancing clinical decision-making and patient outcomes
• Furthermore, connected platforms allow for centralized management of patient data, enabling healthcare professionals to integrate gas exchange test results with broader pulmonary health records. This is especially beneficial in multi-specialty environments or in cases of chronic condition monitoring
• Devices such as the Diffustik and Innocor from prominent European manufacturers allow clinicians to automate test procedures, thereby reducing technician involvement and improving test repeatability. These technologies ensure standardization across clinics and are becoming essential in modern pulmonary labs
• The growing preference for digital and automated diagnostic tools is reshaping expectations in pulmonary care. As a result, key players like NDD Medical Technologies and Geratherm Respiratory GmbH are enhancing their offerings with features such as touchscreen interfaces, wireless data transfer, and cloud-based reporting systems
• This drive toward greater convenience, accuracy, and integration is fueling rapid adoption across the region, especially as demand increases for scalable and portable solutions in both urban hospital settings and remote diagnostic programs

Europe Gas Exchange Pulmonary Function Testing Market Dynamics

Driver

“Growing Need Due to Rising Respiratory Disorders and Early Diagnostic Demand”

• The increasing burden of chronic respiratory diseases, such as COPD, asthma, interstitial lung disease, and pulmonary hypertension across Europe, is significantly driving the demand for gas exchange pulmonary function testing
  • For instance, in 2024, the European Respiratory Society (ERS) highlighted a rising incidence of chronic lung conditions, particularly among aging populations and urban dwellers exposed to pollution. As a result, hospitals and clinics are prioritizing early detection using non-invasive pulmonary diagnostics
• The growing awareness among patients and physicians regarding early and accurate lung function monitoring is accelerating the adoption of gas exchange tests, including diffusion capacity and gas distribution testing
• Moreover, the surge in post-COVID-19 respiratory complications and long-COVID symptoms has further increased the importance of routine pulmonary assessments using gas exchange analysis
• The availability of portable and user-friendly systems, especially in outpatient and home care settings, is expanding access to these tests. Additionally, integration with electronic health records (EHRs) and AI-based interpretation tools enhances clinical efficiency and supports broader adoption across Europe

Restraint/Challenge

“High Cost of Equipment and Limited Access in Rural Settings”

• One of the primary restraints for market expansion is the high capital cost associated with installing advanced gas exchange pulmonary function testing equipment, particularly for smaller diagnostic labs and specialty clinics
• In addition, rural and underserved regions across parts of Eastern Europe often lack access to modern pulmonary diagnostics due to insufficient infrastructure, lower healthcare funding, and lack of trained personnel
  • For instance, advanced diffusion capacity testing systems with integrated software can cost substantially more than basic spirometry tools, creating a budgetary barrier for wide-scale deployment
• To mitigate these challenges, manufacturers must focus on cost-effective, portable, and easy-to-use devices while healthcare policymakers should incentivize technology adoption through public-private partnerships, training programs, and reimbursement support
• Overcoming these limitations will be essential to improve equitable access and ensure widespread usage of gas exchange pulmonary function testing in both urban and rural Europe

Europe Gas Exchange Pulmonary Function Testing Market Scope

The market is segmented on the basis of test type, system type, application, and end user.

• By Test Type

On the basis of test type, the Europe gas exchange pulmonary function testing market is segmented into diffusion capacity test and gas distribution test. Diffusion capacity test held the largest market share of 64.3% in 2024, due to its essential role in diagnosing diseases like pulmonary fibrosis and emphysema. Its non-invasive nature and broad clinical application support its dominance.

Gas distribution test is projected to grow at the fastest CAGR of 7.6% from 2025 to 2032, driven by demand for early-stage lung function evaluation and precision diagnostics.

• By System Type

On the basis of system type, the market is segmented into portable and stationary. Stationary Systems dominated the market with a 68.2% share in 2024 due to their extensive use in hospitals and diagnostic labs for comprehensive pulmonary testing.

Portable Systems segment is expected to grow at fastest CAGR of 8.9% from 2025 to 2032, driven by the rise of home healthcare, mobile diagnostics, and telemedicine integration.

• By Application

On the basis of application, the market is segmented into chronic obstructive pulmonary disease (COPD), asthma, chronic shortness of breath, pulmonary embolism, pulmonary hypertension, sarcoidosis, interstitial fibrosis, restrictive lung disease, lung haemorrhage, and others. Chronic Obstructive Pulmonary Disease (COPD) held the largest market share of 32.7% in 2024 due to its high prevalence and dependence on gas exchange testing for management.

Asthma is expected to witness the fastest CAGR from 2025 to 2032, driven by increasing diagnosis and routine respiratory monitoring.

• By End User

On the basis of end user, the market is segmented into hospitals, specialty clinics, diagnostic laboratories, and others. Hospitals segment dominated with a 49.6% share in 2024, attributed to advanced infrastructure, skilled personnel, and integration of gas exchange tests into inpatient care.

Specialty Clinics is expected to witness the fastest CAGR from 2025 to 2032, benefitting from focused respiratory care and outpatient diagnostics.

Europe Gas Exchange Pulmonary Function Testing Market Regional Analysis

• Europe dominated the global gas exchange pulmonary function testing Market with a revenue share of 40.01% in 2024, driven by increased awareness of pulmonary disorders, early adoption of diagnostic tools, and strong public health initiatives across the region
• Rising prevalence of conditions such as COPD, pulmonary fibrosis, and sarcoidosis, combined with government-supported respiratory health screening, is fueling market demand
• Countries like the U.K. and Germany are leading the charge, with expanding applications in hospitals, specialty clinics, and diagnostic laboratories

U.K. Gas Exchange Pulmonary Function Testing Market

The U.K. gas exchange pulmonary function testing Market accounted for the largest share in Europe at 26.8% in 2024, owing to the strong focus of the NHS on respiratory diagnostics, early intervention, and widespread access to pulmonary testing services. Continuous upgrades in diagnostic equipment, national lung health programs, and clinical research initiatives are boosting growth in both urban hospitals and community healthcare settings.

Germany Gas Exchange Pulmonary Function Testing Market

The Germany gas exchange pulmonary function testing Market is the fastest-growing in Europe, with a projected CAGR of 7.8% during the forecast period (2025–2032). Holding a 22.3% share of the European market in 2024, growth is fueled by strong R&D infrastructure, digital health integration, and widespread use of gas exchange systems in academic and tertiary care hospitals. Government incentives to adopt advanced pulmonary diagnostic solutions are further supporting expansion.

France Gas Exchange Pulmonary Function Testing Market

The France gas exchange pulmonary function testing market represented 17.2% of the European share in 2024, supported by high awareness of chronic respiratory illnesses, state-led diagnostic reforms, and increased funding for hospital respiratory units. The adoption of portable and stationary gas exchange systems in rural hospitals is also improving accessibility.

Italy Gas Exchange Pulmonary Function Testing Market

The Italy gas exchange pulmonary function testing Market captured 13.4% of the European market in 2024, driven by the increasing burden of respiratory diseases, a growing elderly population, and national efforts to modernize diagnostic capabilities in public hospitals. Collaborations with EU health agencies and a rise in specialty respiratory centers are accelerating market growth.

Europe Gas Exchange Pulmonary Function Testing Market Share

The Europe gas exchange pulmonary function testing market industry is primarily led by well-established companies, including:

• VYAIRE (U.S.)
• Geratherm Respiratory GmbH (Germany)
• M.E.C. MEDICAL ELECTRONIC CONSTRUCTION (Italy)
• ECO MEDICS AG (Switzerland)
• PulmOne Advanced Medical Devices (U.S.)
• Data Sciences International (U.S.)
• medical equipment europe GmbH (Germany)
• NDD Medical Technologies (Switzerland)
• MGC DIAGNOSTICS CORPORATION (U.S.)
• SCHILLER (Switzerland)
• Medisoft Group (France)
• Biodex Medical Systems, Inc. (U.S.)
• COSMED srl (Italy)
• PISTON MEDICAL (Italy)
• CARESTREAM MEDICAL (U.S.)
• KoKo PFT (U.S.)
• ASI Health Services (U.S.)
• Swedish Health Services (Sweden)
• Bellin Health Systems (U.S.)

Latest Developments in Europe Gas Exchange Pulmonary Function Testing Market

• In June 2021, the NDD Medical Technologies had improved and increased the product portfolio of gas exchange pulmonary function testing., such as EasyOne Air, Easy on-PC, EasyOne Pro, and EasyOne Pro LAB. The addition of products in the product range would result in a rise in net sales of the products, ease of availability, and a rise in customers from hospitals and diagnostic laboratories in Europe
•  In April 2024, ndd Medical Technologies received MDR (Medical Device Regulation) approval in Europe for its EasyOne Air Spirometer, enabling broader adoption across EU clinical facilities. This certification ensures the device meets stringent EU safety and performance requirements, promoting confidence among hospitals and diagnostic centers across Europe.
• In December 2024, ndd Medical Technologies launched the EasyOne Sky, a next-generation handheld spirometer with a built-in patient-coaching system and TrueFlow ultrasound technology. This innovation is expected to enhance diagnostic efficiency and increase accessibility to pulmonary function testing, particularly in remote and outpatient settings across Europe.
• In April 2021, Vyaire Medical introduced the ARTiQ.PFT software in the European market, integrating artificial intelligence to automatically interpret gas exchange testing data. This solution significantly improves clinician workflow and diagnostic accuracy, helping expand the use of PFT systems across hospitals and clinics in Europe.

SKU-66508